Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2013; 19(33): 5542-5550
Published online Sep 7, 2013. doi: 10.3748/wjg.v19.i33.5542
Table 1 Case characteristics n (%)
CharacteristicsIBL (mL)
χ2P value
< 200200-400> 400
IBL (mean ± SD)99.3 ± 25.0223.2 ± 41.6484.4 ± 179.9
Gender4.3070.116
Male269 (70.2)285 (71.6)53 (71.8)
Female114 (29.8)113 (28.4)11 (28.2)
Age (yr)2.4880.288
≤ 65230 (60.1)227 (57.0)32 (50.0)
> 65153 (39.9)171 (43.0)32 (50.0)
Tumor location40.555< 0.001
Lower 1/3205 (53.5)148 (37.2)14 (21.9)
Middle 1/336 (9.4)41 (10.3)6 (9.4)
Upper 1/398 (25.6)164 (41.2)34 (53.1)
2/3 or more44 (11.5)45 (11.3)10 (15.6)
Tumor size17.677< 0.001
< 5 cm180 (47.0)155 (38.9)13 (20.3)
≥ 5 cm203 (53.0)243 (61.1)51 (79.7)
Borrmann type5.1800.075
I/II169 (44.1)153 (38.4)33 (51.6)
III/IV214 (55.9)245 (61.6)31 (48.4)
Histology0.9820.612
Differentiated121 (31.6)139 (34.9)21 (32.8)
Undifferentiated262 (68.4)259 (65.1)43 (67.2)
Extranodal metastasis1.9630.375
Positive59 (15.4)71 (17.8)14 (21.9)
Negative324 (84.6)327 (82.2)50 (78.1)
Depth of invasion14.7190.023
pT114 (3.7)11 (2.8)0 (0.0)
pT253 (13.8)44 (11.1)0 (0.0)
pT321 (5.5)28 (7.0)6 (9.4)
pT4295 (77.0)315 (79.1)58 (90.6)
Lymph node metastasis15.7930.015
pN0173 (45.2)146 (36.7)19 (29.7)
pN156 (14.6)82 (20.6)9 (14.1)
pN285 (22.2)87 (21.9)15 (23.4)
pN369 (18.0)83 (20.9)21 (32.8)
TNM stage15.3130.004
I53 (13.8)43 (10.8)0 (0.0)
II132 (34.5)118 (29.6)19 (29.7)
III198 (51.7)237 (59.5)45 (70.3)
Chemotherapy2.0360.361
Yes104 (27.2)119 (29.9)14 (21.9)
No279 (72.8)279 (70.1)50 (78.1)
Type of gastrectomy37.357< 0.001
Total51 (13.3)117 (29.4)24 (37.5)
Subtotal332 (86.7)281 (70.6)40 (62.5)
Combined organ resection22.256< 0.001
Yes16 (4.2)38 (9.5)13 (20.3)
No367 (95.8)360 (90.5)51 (79.7)
Extent of lymphadenectomy7.2300.027
D2 and D2+189 (49.3)188 (47.2)20 (31.3)
D1194 (50.7)210 (52.8)44 (68.8)
Postoperative complications7.5000.024
Present20 (5.2)34 (8.5)9 (14.1)
Absent363 (94.8)364 (91.5)55 (85.9)
Table 2 Survival analysis of all patients with gastric cancer
Characteristicsn (%)5-yr OSUnivariate analysis
Multivariate analysis
χ2P valueHR (95%CI)P value
Gender1.6090.205
Male607 (71.8)42.20%
Female238 (28.2)47.10%
Age (yr)21.037< 0.001
≤ 65489 (57.9)50.10%1 (ref)
> 65356 (42.1)34.60%1.372 (1.140-1.652)0.001
Tumor location26.417< 0.001
Lower 1/3367 (43.4)50.10%1 (ref)
Middle 1/383 (9.8)45.80%0.978 (0.680-1.407)0.905
Upper 1/3296 (35.0)39.50%0.931 (0.741-1.169)0.538
2/3 or more99 (11.7)29.30%1.149 (0.832-1.586)0.398
Tumor size58.693< 0.001
< 5 cm348 (41.2)57.80%1 (ref)
≥ 5 cm497 (58.8)33.60%1.411 (1.152-1.730)0.001
Borrmann type13.517< 0.001
I/II355 (42.0)50.40%1 (ref)
III/IV490 (58.0)38.60%1.285 (1.062-1.556)0.010
Histology6.7830.009
Differentiated281 (33.3)49.80%1 (ref)
Undifferentiated564 (66.7)40.40%1.151 (0.939-1.412)0.176
Extranodal metastasis52.773< 0.001
Negative701 (83.0)47.50%1 (ref)
Positive144 (17.0)24.30%1.543 (1.236-1.925)< 0.001
TNM stage147.103< 0.001
I96 (11.4)82.30%1 (ref)
II269 (31.8)58.40%2.253 (1.362-3.727)0.002
III480 (56.8)27.50%4.736 (2.898-7.740)< 0.001
Chemotherapy10.9990.001
Yes237 (28.0)50.60%1 (ref)
No608 (72.0)40.80%1.357 (1.093-1.684)0.006
Extent of lymphadenectomy6.6680.010
D2 and D2+397 (47.0)48.40%1 (ref)
D1448 (53.0)39.30%1.372 (1.126-1.671)0.002
Type of gastrectomy21.400< 0.001
Subtotal653 (77.3)47.00%1 (ref)
Total192 (22.7)31.80%1.102 (0.849-1.430)0.466
Combined organ resection10.3100.001
No778 (92.1)44.60%1 (ref)
Yes67 (7.9)31.30%1.116 (0.811-1.536)0.501
Intraoperative blood loss29.175< 0.001
< 200 mL383 (45.3)51.20%1 (ref)
200-400 mL398 (47.1)39.40%1.242 (1.017-1.516)0.033
> 400 mL64 (7.6)23.40%1.590 (1.140-2.217)0.006
Perioperative transfusion6.1450.013
No634 (75.0)45.70%1 (ref)
Yes211 (25.0)37.00%0.962 (0.748-1.180)0.708
Postoperative complications28.320< 0.001
Absent782 (92.5)44.90%1 (ref)
Present63 (7.5)27.00%2.096 (1.525-2.881)< 0.001
Table 3 Tumour-node-metastasis-stratified analysis of the overall survival
Group 11
Group 21
Group 31
χ2P value
n5-yr OSn5-yr OSn5-yr OS
TNM
I5388.74374.44.5380.037
II13268.211850.01942.110.7630.005
III19829.823727.84515.68.0350.018
Table 4 Association between clinicapothologic factors and the amount of intraoperative blood loss: univariate analysis
Characteristicsn (%)Amount of IBL (mL) (mean ± SD)t/FP value
Gender1.7700.077
Male607 (71.8)191.4 ± 128.6
Female238 (28.2)175.2 ± 92.5
Age (yr)-1.1280.260
≤ 65489 (57.9)182.9 ± 121.8
> 65356 (42.1)192.3 ± 116.7
Tumor location12.455< 0.001
Lower 1/3367 (43.4)160.9 ± 87.8
Middle 1/383 (9.8)179.5 ± 103.0
Upper 1/3296 (35.0)213.2 ± 127.5
2/3 or more99 (11.7)210.6 ± 177.5
Tumor size-4.129< 0.001
< 5 cm348 (41.2)166.7 ± 92.8
≥ 5 cm497 (58.8)200.9 ± 133.7
Borrmann type
I/II355 (42.0)187.5 ± 127.0 0.1280.899
III/IV490 (58.0)186.4 ± 114.3
Histology-0.1600.873
Differentiated281 (33.3)185.9 ± 107.7
Undifferentiated564 (66.7)187.3 ± 125.3
Extranodal metastasis-1.0400.299
Negative701 (83.0)184.9 ± 119.7
Positive144 (17.0)196.3 ± 119.6
TNM stage4.9740.007
I96 (11.4)154.2 ± 67.1
II269 (31.8)183.3 ± 135.9
III480 (56.8)195.4 ± 117.1
Type of gastrectomy-5.963< 0.001
Subtotal653 (77.3)173.8 ± 102.3
Total192 (22.7)231.2 ± 158.1
Combined organ resection-5.329< 0.001
Absent778 (92.1)180.5 ± 110.9
Present67 (7.9)260.4 ± 180.0
Extent of llymphadenectomy-2.6760.008
D2 and D2+397 (47.0)175.2 ± 95.4
D1448 (53.0)197.2 ± 136.9
Year of surgery-2.4940.013
2003-2005489 (57.9)195.1 ± 133.6
2006-2007356 (42.1)174.3 ± 97.6
Table 5 Multivariate analysis of risk factors for intraoperative blood loss ≥ 200 mL
FeatureHR95%CIP value
Tumor locationUpper 1/3 and 2/3 or more vs lower and middle 1/31.7171.272-2.317< 0.001
Tumor size≥ 5 cm vs < 5 cm1.1290.833-1.5130.434
TNM stageIII vs I, II1.1740.872-1.5800.290
Extent of gastrectomyD1 vs D2 and D2+1.1610.860-1.5660.330
Type of gastrectomyTotal vs subtotal2.5011.707-3.663< 0.001
Combined organ resectionPresent vs absent1.9961.089-3.6590.025
Year of surgery2003-2005 vs 2006-20071.4521.080-1.9540.014